Sabari et al. - Google Patents
A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC PD-L1 EXPRESSION IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC)Sabari et al.
View PDF- Document ID
- 4348493305709934449
- Author
- Sabari J
- Rangachari D
External Links
Snippet
Clinical Research Protocol Page 1 CONFIDENTIAL This material is the property of the NYU
School of Medicine and Langone Medical Center. Do not disclose or use except as authorized
in writing by the study sponsor A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC …
- 229960002621 pembrolizumab 0 title description 274
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sabari et al. | A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC PD-L1 EXPRESSION IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC) | |
Russo | Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (< 50%) _ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors) | |
Bahce et al. | Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study | |
Sundahl et al. | Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma | |
CONFIDENTIAL et al. | A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab | |
CONFIDENTIAL et al. | Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155) IND NUMBER: Pembrolizumab 118,604; Dinaciclib 114,461 EudraCT NUMBER: Not Applicable NCT NUMBER: NCT02684617 | |
Richart et al. | Phase 2B single-site, open-label, nonrandomized study evaluating the efficacy of neoadjuvant MK-3475 for unresectable Stage III and unresectable Stage IV melanoma | |
CONFIDENTIAL et al. | Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)(KEYNOTE-199) | |
CONFIDENTIAL et al. | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine | |
CONFIDENTIAL et al. | A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma | |
Borghaei | Supported by Merck and Celgene | |
CONFIDENTIAL et al. | A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors | |
CONFIDENTIAL et al. | A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+ 5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059). | |
Leemans | Short title NeoNivo EudraCT number 2018-002643-28 Version 9 Date 11-12-2019 Principal investigators C. Willemien Menke-van der Houven van Oordt, MD PhD | |
Uronis | A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients with Gastro-esophageal Cancer | |
CONFIDENTIAL et al. | A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS) | |
Vijayvergia | GI-087 A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients with Previously Treated Metastatic High Grade Neuroendocrine tumors | |
CLINICIANS et al. | 1500 E. DUARTE ROAD DUARTE, CA 91010 DEPARTMENT OF MEDICAL ONCOLOGY | |
Mark Awad | Biomarkers of response to ipilimumab and nivolumab as first-line therapy for metastatic non-small cell lung cancer (NSCLC): an open-label, single arm phase 2 study Coordinating Center: Dana-Farber Cancer Institute (DFCI) | |
Mascarenhas et al. | PD-1 inhibition in advanced myeloproliferative neoplasms | |
Tolaney | A randomized phase II study of eribulin mesylate with or without pembrolizumab for metastatic hormone receptor positive breast cancer | |
CONFIDENTIAL et al. | A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer | |
CONFIDENTIAL et al. | A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC)–(KEYNOTE-086) | |
Holder et al. | Sub-Investigator (s): Developmental Therapeutics Program of Division of Hematology Oncology | |
Schlom | OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy |